Background: Bullous pemphigoid (BP) is an autoimmune blistering disease that is associated with increased mortality.

Objective: We sought to determine the incidence and mortality of patients with BP.

Methods: A total of 87 residents of Olmsted County, Minnesota, were identified who had their first lifetime diagnosis of BP from January 1960 through December 2009. Incidence and mortality were compared with age- and sex-matched control patients from the same geographic area.

Results: The adjusted incidence of BP was 2.4 per 100,000 person-years (95% confidence interval, 1.9-2.9). Incidence of BP increased significantly with age (P < .001) and over time (P = .034). Trend tests indicate increased diagnosis of localized disease (P = .006) may be a contributing factor. Survival observed in the incident BP cohort was significantly poorer than expected (P < .001). Survival was not different among patients with multisite versus localized disease (P = .90).

Limitations: Retrospective study design and study population from a small geographic area are limitations.

Conclusion: Incidence of BP in the United States is comparable with that found in Europe and Asia. The mortality of BP is lower in the United States than Europe, but higher than previous estimates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324601PMC
http://dx.doi.org/10.1016/j.jaad.2014.02.030DOI Listing

Publication Analysis

Top Keywords

bullous pemphigoid
12
mortality patients
8
olmsted county
8
county minnesota
8
incidence mortality
8
localized disease
8
disease p =
8
united states
8
incidence
6
incidence bullous
4

Similar Publications

Clinical characteristics of bullous pemphigoid patients of different ages and the possible mechanism.

J Dermatol

January 2025

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Bullous pemphigoid (BP) is an acquired autoimmune bullous disease that often occurs in elderly patients. Some BP patients with early age of disease onset were observed to have difficulty in receiving applicable disease control. It remains challenging for clinicians to choose the appropriate treatment for these patients.

View Article and Find Full Text PDF

Dyshidrosiform bullous pemphigoid (DBP) is a rare variant of bullous pemphigoid (BP) that mainly affects elderly patients and presents with tense bullae formation on the palms, soles, or both palms and soles. This case report describes an 87-year-old woman who was evaluated in the hospital for a month-long erythematous and pruritic rash on most of her body that eventually manifested into tense blisters on the palms. DBP can pose a challenge to clinicians as it can resemble a variety of different vesicular diseases.

View Article and Find Full Text PDF

Investigation of Consultations Requested by Dermatology Inpatient.

Clin Cosmet Investig Dermatol

January 2025

Department of Dermatology, Çukurova University, Faculty of Medicine, Adana, Turkey.

Background: Although dedicated dermatology wards have been closed in some countries, they continue to exist in others. Inpatient consultations requested from dermatologists have been investigated widely. However, those requested by dermatologists have been taken into consideration only in a few studies.

View Article and Find Full Text PDF

Bullous pemphigoid (BP) is an autoimmune blistering disorder predominantly affecting the elderly. Recently, many studies have shed light on the effect of specific drug intake and comorbidities on the development of BP. The purpose of this study was to investigate the association of specific drug class intake and comorbidities with the development of BP in the Cretan population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!